Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | December 05, 2020 | December 07, 2020 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director · Director, President and CEO | February 12, 2020 | February 12, 2020 |
| ECOLAB INC.ECL · Entity 2954 | Director | March 31, 2025 | April 02, 2025 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date December 05, 2020 · Filed December 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 564,239 |
Reported balance
After 2020-12-05 transaction · row 1
1 source rowRow 1 · 2020-12-05 · Exercise / conversion · Acquired 73,529 · Balance 564,239 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-05 | Direct | 0 |
Reported balance
After 2020-12-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-05 · Exercise / conversion · Disposed 73,529 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Assertio Therapeutics, Inc
Report date February 12, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 244,739 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 97,412 · Balance 275,747 Row 2 · 2020-02-12 · Tax withholding · Disposed 31,008 · Balance 244,739 F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-12 | Direct | 194,825 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Exercise / conversion · Disposed 97,412 · Balance 194,825 F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
ECOLAB INC.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,741.32 |
Reported balance
After 2025-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-31 · Grant · Acquired 134.16 · Balance 26,741.32 F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. |
| Common StockSEC Table I · non-derivative | Direct | 26,865.54 |
Reported balance
After 2025-03-31 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-31 · Grant · Acquired 124.22 · Balance 26,865.54 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 38,077.496 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 306.066 · Balance 38,077.496 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2019 Filed Feb 7, 2019 21:07 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Tax withholdingCommon Stock | 18,927 | $4.48 | $84,792.96 |
DisclosureSEC source: 0001005201-19-000006 · wf-form4_154957363092978.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,879 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:07 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 62,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000006 · wf-form4_154957363092978.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:20 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 188.32 | $146.03 | $27,500.37 |
DisclosureSEC source: 0001179110-19-000288 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,701.89 F1 · balance_after: Includes 47.22 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:20 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 196.88 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000288 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,466.35 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 265.931 | $0.00 Strike: $103.41 | $0.00 |
DisclosureSEC source: 0000911916-19-000006 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,631.749 Underlying: Common Stock · 265.931 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 46.233 phantom stock units accrued on October 31, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:05 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 34,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-18-000017 · wf-form4_154393951707423.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,720 Underlying: Common Stock · 34,861 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:05 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Tax withholdingCommon Stock | 10,215 | $4.99 | $50,972.85 |
DisclosureSEC source: 0001005201-18-000017 · wf-form4_154393951707423.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,406 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:05 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 34,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-18-000017 · wf-form4_154393951707423.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 20:56 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 175.56 | $156.65 | $27,500.60 |
DisclosureSEC source: 0001179110-18-011921 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,269.47 F1 · balance_after: Includes 47.25 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 20:56 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 183.54 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-011921 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,046.66 Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 20:00 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 210.486 | $0.00 Strike: $130.65 | $0.00 |
DisclosureSEC source: 0000911916-18-000180 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,319.585 Underlying: Common Stock · 210.486 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 41.613 phantom stock units accrued on July 31, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:55 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionNon-Employee Director Stock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $51.74 | $0.00 |
DisclosureSEC source: 0001179110-18-010994 · edgar.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,200 shares Expires 2021-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant. The date listed in the "Date Exercisable" column represents the first vesting date. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:55 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionNon-Employee Director Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $47.48 | $0.00 |
DisclosureSEC source: 0001179110-18-010994 · edgar.xml · derivative · entry 4 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant. The date listed in the "Date Exercisable" column represents the first vesting date. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:55 UTC | ECOLAB INC. ECL · Entity 2954 | SaleCommon Stock | 8,700 | $149.76 | $1,302,946.80 |
DisclosureSEC source: 0001179110-18-010994 · edgar.xml · nonDerivative · entry 3 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,863.12 F1 · price: This transaction was executed in multiple trades at prices ranging from $149.75 to $149.84, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:55 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionCommon Stock | 4,200 | $51.74 | $217,287.00 |
DisclosureSEC source: 0001179110-18-010994 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,563.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:55 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionCommon Stock | 4,500 | $47.48 | $213,637.50 |
DisclosureSEC source: 0001179110-18-010994 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,363.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 21:11 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 195.07 | $140.98 | $27,499.99 |
DisclosureSEC source: 0001179110-18-009373 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,863.12 F1 · balance_after: Includes 45.52 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 21:11 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 203.94 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009373 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,622.53 Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 20:07 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 244.771 | $0.00 Strike: $112.35 | $0.00 |
DisclosureSEC source: 0000911916-18-000136 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,067.486 Underlying: Common Stock · 244.771 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,143.159 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-18-000125 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,762.459 Underlying: Common Stock · 1,143.159 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $113.72 | $0.00 |
DisclosureSEC source: 0000911916-18-000125 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,822.715 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 43.401 phantom stock units accrued on April 30, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:02 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $144.02 | $0.00 |
DisclosureSEC source: 0001179110-18-006310 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2028-05-03 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:52 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 201.56 | $136.44 | $27,499.84 |
DisclosureSEC source: 0001179110-18-005246 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,418.59 F1 · balance_after: Includes 46.41 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:52 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 210.72 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005246 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,170.62 Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 19:11 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 253.199 | $0.00 Strike: $108.61 | $0.00 |
DisclosureSEC source: 0000911916-18-000107 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,279.314 Underlying: Common Stock · 253.199 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 38.987 phantom stock units accrued on January 29, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 06, 2018 Filed Feb 9, 2018 01:15 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 187,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001862 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,200 Underlying: Common Stock · 187,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021, assuming continued employment through the applicable vesting date. F2 · derivative.expiration_date: These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021, assuming continued employment through the applicable vesting date. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:04 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 194.67 | $134.85 | $26,250.28 |
DisclosureSEC source: 0001179110-18-000325 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,959.9 F1 · balance_after: Includes 41.66 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:04 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 185.4 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-000325 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,723.57 Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 18:30 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 226.73 | $0.00 Strike: $121.29 | $0.00 |
DisclosureSEC source: 0000911916-18-000016 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,987.128 Underlying: Common Stock · 226.73 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 40.469 phantom stock units accrued on October 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 22:36 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 73,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015442 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,529 Underlying: Common Stock · 73,529 shares Expires 2027-12-14 F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · shares: These Restricted Stock Units were granted pursuant to the one-time incentive program for the Company's Chief Executive Officer which was approved by the Board on December 6, 2017. F3 · derivative.exercise_date: These restricted stock units are scheduled to fully vest on December 5, 2020, assuming continued employment through the applicable vesting date. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 22:36 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | PurchaseCommon Stock | 75,000 | $8.16 | $612,000.00 |
DisclosureSEC source: 0001179110-17-015442 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,760 F1 · balance_after: Amount excludes 1,000 shares of common stock held indirectly by Child but includes 15,000 shares held indirectly by Family Trust. Read SEC document |
| December 01, 2017 Filed Dec 6, 2017 01:21 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | Tax withholdingCommon Stock | 13,101 | $7.11 | $93,148.11 |
DisclosureSEC source: 0001179110-17-014991 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,760 F2 · shares: Represents shares of restricted stock forfeited to meet the tax liability triggered by the vesting of such stock. F1 · balance_after: Amount does not include 1,000 shares of common stock held indirectly by Child but includes 15,000 shares held indirectly by Family Trust. F3 · balance_after: Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:58 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 203.35 | $129.09 | $26,250.45 |
DisclosureSEC source: 0001179110-17-012983 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,538.17 F1 · balance_after: Includes 41.12 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:58 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 193.66 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012983 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,293.7 Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 12:56 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 236.519 | $0.00 Strike: $116.27 | $0.00 |
DisclosureSEC source: 0000911916-17-000236 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,719.929 Underlying: Common Stock · 236.519 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 39.467 phantom stock units accrued on July 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:17 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 198.08 | $132.52 | $26,249.56 |
DisclosureSEC source: 0001179110-17-010055 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,100.04 F1 · balance_after: Includes 42.19 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:17 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 188.65 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010055 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,859.77 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:53 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 208.317 | $0.00 Strike: $128.41 | $0.00 |
DisclosureSEC source: 0000911916-17-000213 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,443.943 Underlying: Common Stock · 208.317 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 17:17 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | PurchaseCommon Stock | 15,000 | $9.92 | $148,800.00 |
DisclosureSEC source: 0001179110-17-008974 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,000 F1 · balance_after: Amount does not include 1,000 shares of common stock held indirectly by Child. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:11 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,067.85 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000172 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,619.3 Underlying: Common Stock · 1,067.85 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:11 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $121.74 | $0.00 |
DisclosureSEC source: 0000911916-17-000172 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,235.626 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 39.900 phantom stock units accrued on April 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:52 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $125.67 | $0.00 |
DisclosureSEC source: 0001179110-17-006685 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-05-04 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:53 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 209.46 | $125.32 | $26,249.53 |
DisclosureSEC source: 0001179110-17-005625 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,671.12 F1 · balance_after: Includes 43.08 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:53 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 199.49 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005625 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,418.58 Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 00:32 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Units · Derivative | 139,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005728 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,442 Underlying: Common Stock · 139,442 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020, assuming continued employment through the applicable vesting date. Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 00:32 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantStock Options · Derivative | 315,884 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001179110-17-005728 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,884 Underlying: Common Stock · 315,884 shares Expires 2027-03-31 F1 · derivative.exercise_date: Exercisable with respect to 12.5% of the underlying shares on September 28, 2017, and in 42 equal monthly installments thereafter, such that the stock options will be fully vested and exercisable on March 28, 2021. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 220.182 | $0.00 Strike: $121.49 | $0.00 |
DisclosureSEC source: 0000911916-17-000151 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,695.726 Underlying: Common Stock · 220.182 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 39.453 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:09 UTC | ECOLAB INC. ECL · Entity 2954 | SaleCommon Stock | 5,000 | $125.10 | $625,500.00 |
DisclosureSEC source: 0001179110-17-003497 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,219.09 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:24 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 223.22 | $117.60 | $26,249.56 |
DisclosureSEC source: 0001179110-17-000209 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,219.09 F1 · balance_after: Includes 40.02 shares acquired under a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:24 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 212.59 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000209 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,955.85 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.